Obinutuzumab vs rituximab for relapsing childhood kidney syndrome
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is age 3 to 18 years
- Your child has steroid-dependent or frequent-relapsing nephrotic syndrome, with specific timing and number of relapses
- Your child is in remission right before randomization (three urine dipstick tests without protein)
- Your child has had no rituximab in the last 6 months, and no obinutuzumab ever
- Your child’s blood counts and kidney function meet limits (including minimum white blood cells/platelets and kidney filtration)
- Vaccines are up to date, and no live vaccine within the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests rituximab, a medicine that affects the immune system, in children who have their first episode of steroid-sensitive nephrotic syndrome and are in remission at enrollment. It aims to see whether rituximab helps prevent relapse and improves kidney outcomes with fewer steroid needs.
This trial tests a medication called obinutuzumab for people with lupus-related kidney disease, specifically a type called pure membranous nephropathy. The goal is to see if it helps reduce protein leaking into the urine and improves kidney health.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests a new drug called obinutuzumab for adults whose nephrotic syndrome (a kidney disease causing swelling and protein in urine) has relapsed after stopping rituximab. It aims to see if obinutuzumab can help prevent future relapses.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests whether rituximab works as well as mycophenolate in children whose nephrotic syndrome (kidney condition) comes back when steroid medicines are reduced. It aims to find the safest and most effective option during a relapse.
Hear when a new Steroid-Sensitive Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.